Display options
Cite
Belling M, Kanate AS, Shillingburg A, et al. Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. Leuk Res Treatment. 2017;2017:3460892doi: 10.1155/2017/3460892.
Belling, M., Kanate, A. S., Shillingburg, A., Lu, X., Wen, S., Shah, N., Craig, M., & Cumpston, A. (2017). Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. Leukemia research and treatment, 20173460892. https://doi.org/10.1155/2017/3460892
Belling, Morgan, et al. "Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation." Leukemia research and treatment vol. 2017 (2017): 3460892. doi: https://doi.org/10.1155/2017/3460892
Belling M, Kanate AS, Shillingburg A, Lu X, Wen S, Shah N, Craig M, Cumpston A. Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. Leuk Res Treatment. 2017;2017:3460892. doi: 10.1155/2017/3460892. Epub 2017 Jun 11. PMID: 28695013; PMCID: PMC5485328.
Copy Download .nbib Format: NLM
Share it on

Leuk Res Treatment. 2017;2017:3460892. doi: 10.1155/2017/3460892. Epub 2017 Jun 11.

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation.

Leukemia research and treatment

Morgan Belling, Abraham S Kanate, Alexandra Shillingburg, Xiaoxiao Lu, Sijin Wen, Nilay Shah, Michael Craig, Aaron Cumpston

Affiliations

  1. Department of Pharmacy, West Virginia University Hospitals, Morgantown, WV, USA.
  2. Osborn Hematopoietic Malignancy and Transplantation Program, MBRCC, West Virginia University, Morgantown, WV, USA.
  3. Department of Biostatistics, West Virginia University, Morgantown, WV, USA.

PMID: 28695013 PMCID: PMC5485328 DOI: 10.1155/2017/3460892

Abstract

Posaconazole (PCZ) is frequently used for prophylaxis against invasive fungal infections (IFI) in patients undergoing induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Posaconazole is commercially available as an oral suspension (PCZ-susp) and as a delayed-release tablet (PCZ-tab). Differences in absorption and bioavailability between these formulations may result in variability in serum posaconazole concentrations. The primary objective of this retrospective analysis was to compare attainment of goal serum posaconazole steady state concentrations (

References

  1. Antimicrob Agents Chemother. 2015 Aug;59(8):4914-8 - PubMed
  2. N Engl J Med. 2007 Jan 25;356(4):335-47 - PubMed
  3. Clin Infect Dis. 2008 Jun 15;46(12):1813-21 - PubMed
  4. Antimicrob Agents Chemother. 2015 Aug;59(8):4424-8 - PubMed
  5. Antimicrob Agents Chemother. 2012 Nov;56(11):5503-10 - PubMed
  6. Mycoses. 2016 Jan 6;:null - PubMed
  7. Mycoses. 2015 Jul;58(7):432-6 - PubMed
  8. Mycoses. 2015 Jun;58(6):362-7 - PubMed
  9. Antimicrob Agents Chemother. 2014 Oct;58(10):5758-65 - PubMed
  10. Int J Antimicrob Agents. 2012 Dec;40(6):557-61 - PubMed
  11. Pharmacotherapy. 2008 Oct;28(10):1223-32 - PubMed
  12. Int J Antimicrob Agents. 2012 Jun;39(6):510-3 - PubMed
  13. Curr Med Res Opin. 2010 Feb;26(2):397-405 - PubMed
  14. Antimicrob Agents Chemother. 2009 Dec;53(12):5224-9 - PubMed
  15. J Antimicrob Chemother. 2016 Mar;71(3):718-26 - PubMed
  16. Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201 - PubMed
  17. Antimicrob Agents Chemother. 2014 Nov;58(11):6993-5 - PubMed
  18. J Antimicrob Chemother. 2014 May;69(5):1162-76 - PubMed
  19. Antimicrob Agents Chemother. 2014 Jul;58(7):4020-5 - PubMed
  20. Antimicrob Agents Chemother. 2003 Sep;47(9):2788-95 - PubMed
  21. Eur J Clin Microbiol Infect Dis. 2012 Feb;31(2):161-7 - PubMed
  22. Br J Clin Pharmacol. 2004 Feb;57(2):218-22 - PubMed
  23. Antimicrob Agents Chemother. 2010 Jan;54(1):207-12 - PubMed
  24. N Engl J Med. 2007 Jan 25;356(4):348-59 - PubMed
  25. Int J Antimicrob Agents. 2011 Mar;37(3):266-9 - PubMed
  26. J Antimicrob Chemother. 2012 Nov;67(11):2725-30 - PubMed

Publication Types

Grant support